2022
Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women’s Health Initiative
Dieli-Conwright CM, Nelson RA, Simon MS, Irwin ML, Neuhouser ML, Reding KW, Crane TE, Manson JE, Nassir R, Shadyab AH, LaMonte M, Qi L, Thomson CA, Kroenke CH, Pan K, Chlebowski RT, Mortimer J. Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women’s Health Initiative. BMC Women's Health 2022, 22: 32. PMID: 35120497, PMCID: PMC8817588, DOI: 10.1186/s12905-022-01614-3.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityCancer-specific mortalityWomen's Health Initiative participantsEarly-stage breast cancerCardiometabolic risk factorsBreast cancer mortalityPhysical activity levelsRisk factor numberPhysical activityBreast cancerRisk factorsCancer mortalityHigher breast cancer-specific mortalityLower breast cancer-specific mortalityInitiative participantsHealth initiativesNational Death Index queryProportional hazards regression modelsHigher physical activity levelsCancer diagnosisMetabolic syndrome componentsBaseline physical activityHigh waist circumferenceMedical record reviewCause mortality risk
2018
The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401).
Ligibel J, Barry W, Alfano C, Hershman D, Irwin M, Neuhouser M, Thomson C, Delahanty L, Frank E, Spears P, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Goodwin P, Carey L, Partridge A, Winer E. The Breast Cancer Weight Loss (BWEL) trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early-stage breast cancer (Alliance A011401). Journal Of Clinical Oncology 2018, 36: tps598-tps598. DOI: 10.1200/jco.2018.36.15_suppl.tps598.Peer-Reviewed Original Research